Marc Hedrick, M.D., President and CEO of Plus Therapeutics (NASDAQ: PSTV), was recently featured in Pharma’s Almanac, where he shared insights on how precision medicine is reshaping the future of oncology.
Precision Medicine in Cancer Care
In the article, Dr. Hedrick emphasized that precision medicine is increasingly central to cancer treatment, enabling therapies to be:
- More targeted focused on the unique biology of a patient’s tumor
- More effective designed to maximize efficacy while limiting collateral damage
- More adaptive able to evolve as tumor biology changes over time
These advancements are helping shift cancer therapy away from “one-size-fits-all” approaches toward personalized, patient-centered treatments.
Plus Therapeutics’ Commitment to Innovation
At Plus Therapeutics, our pipeline of radiotherapeutics aims to combine precision medicine with advanced delivery platforms to address difficult-to-treat cancers, including those affecting the central nervous system.
Our work in external beam radiation therapy (EBRT) alternatives and targeted radiotherapeutics underscores our mission to develop therapies that improve patient outcomes and expand treatment options.
Read the full Pharma’s Almanac article here.
#PlusTherapeutics #PSTV #PrecisionMedicine #Radiotherapeutics #ExternalBeamRadiationTherapy #EBRT #CancerResearch #OncologyInnovation #CancerTreatment #PersonalizedMedicine
Recent Comments